Celldex Therapeutics (CLDX) Posts Narrower than Expected Q2 Loss of 27c/Sh.

August 3, 2011 7:16 AM
Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $1.95 million versus the consensus estimate of $2.43 million.

Categories

Earnings